• 1
    Denardo DG and Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research 2007; 9: 212.
  • 2
    Smyth MJ, Cretney E, Kershaw MH and Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunological Reviews 2004; 202: 275293.
  • 3
    Yoo SY, Lee SY and Yoo NC. Cytokine expression and cancer detection. Medical Science Monitor 2009; 15: RA4956.
  • 4
    Lin WW and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. The Journal of Clinical Investigation 2007; 117: 11751183.
  • 5
    Nicolini A, Carpi A and Rossi G. Cytokines in breast cancer. Cytokine & Growth Factor Reviews 2006; 17: 325337.
  • 6
    Gilbert CA and Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annual Review of Medicine 2013; 64: 4557.
  • 7
    Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y, Shimpo M, Matsushita T, Okada T, Hanazono Y, Kume A, Sato I and Ozawa K. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Research 2003; 63: 50915094.
  • 8
    Gelaleti GB, Jardim BV, Leonel C, Moschetta MG and Zuccari DA. Interleukin-8 as a prognostic serum marker in canine mammary gland neoplasias. Veterinary Immunology and Immunopathology 2012; 146: 106112.
  • 9
    Kim JH, Yu CH, Yhee JY, et al. Lymphocyte infiltration, expression of interleukin (IL)-1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours. Journal of Comparative Pathology 2010; 142(2–3): 177186.
  • 10
    Misdorp W, Else RW, Hellmen E and Lipscomb TP. Histological classification of mammary tumors of the dog and the cat. Armed Forces Institute of Pathology and the American Registry of Pathology and The World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, Washington DC, pp 11–29, 1999.
  • 11
    Cassali GD, Serakides R, Gärtner F and Schmitt FC. Invasive micropapillary carcinoma. A case report. Arquivo Brasileiro de Medicina Veterinária e Zootecnia 2002; 54: 366369.
  • 12
    Cassali GD, Lavalle GE, De Nardi AB, et al. Consensus for the diagnosis, prognosis and treatment of canine mammary tumors. Brazilian Journal of Veterinary Pathology 2011; 4: 153180.
  • 13
    Owen LN. TNM classification of tumors in domestic animals. Geneva, World Health Organization, 1980.
  • 14
    Luiza-Silva M, Campi-Azevedo AC, Batista MA, et al. Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. The Journal of Infectious Diseases 2011; 204: 873883.
  • 15
    Greiner M, Sohr D and Göbel P. A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. Journal of Immunological Methods 1995; 185: 123132.
  • 16
    Estrela-Lima A, Araújo MS, da Costa-Neto JM, et al. Understanding of the immunological heterogeneity of canine mammary carcinomas to provide immunophenotypic features of circulating leukocytes as clinically relevant prognostic biomarkers. Breast Cancer Research and Treatment 2011; 131: 751763.
  • 17
    Misdorp W. Tumors of the mammary gland. In: Tumors in Domestic Animals. 4 edn., DJ Meuten Ed., Iowa, Iowa State Press, 2002: 575606.
  • 18
    Kitchell BE and Loar AS. Diseases of the mammary glands. In: Handbook of Small Animal Practice. 3 edn., RV Morgan Ed., Philadelphia, 1994: 615625.
  • 19
    Morrison WB. Canine and feline mammary tumors. In: Cancer in Dogs and Cats: Medical and Surgical Management. WB Morrison Ed., Baltimore, Williams and Wilkins, 1998: 591598.
  • 20
    E. B. Davidson. Treatment of mammary tumors in dogs and cats. In: Proceedings of the North American veterinary conference. Orlando, 2003.
  • 21
    Yamagami T, Kobayashi T, Takahashi K and Sugiyama M. Prognosis for canine malignant mammary tumors based on TNM and histologic classification. The Journal of Veterinary Medical Science 1996; 58: 10791083.
  • 22
    Fossum TW. Small animal surgery. St. Louis, Mosby-Year Book, 1997: 539544.
  • 23
    L. Williams. Predictors of tumor response. In: Proceedings of the North American veterinary conference, Orlando, Florida, 679681, 2003.
  • 24
    Paoloni M and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature 2008; 8: 147156.
  • 25
    Karayannopoulou M, Kaldrymidou F, Constantinidis TC and Dessiris A. Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. Journal of Comparative Pathology 2005; 133: 246252.
  • 26
    Elston CW and Ellis IO. Pathological prognostic factors in breast cancer. I. The value of the histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991; 19: 403410.
  • 27
    Estrela-Lima A, Araújo MS, Costa-Neto JM, et al. Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer 2010; 10: 256.
  • 28
    Al Murri AM, Hilmy M, Bell J, Wilson C, et al. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. British Journal of Cancer 2008; 99: 10131019.
  • 29
    Macchetti AH, Marana HRC, Silva JS, Andrade JM, et al. Tumor-infiltration CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics 2006; 61: 203208.
  • 30
    Sheu BC, Hsu SM, Ho HN, et al. Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer 1999; 86: 15371543.
  • 31
    Mantovani A, Allavena P, Sica A and Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436444.
  • 32
    Stewart THM and Heppner GH. Immunological enhancement of breast cancer. Parasitology 1997; 115: S141S153.
  • 33
    Snoussi K, Mahfoudh W, Bouaouina N, et al. Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Human Immunology 2006; 67(1–2): 1321.
  • 34
    Moulton JE. Tumors of the mammary gland. In: Tumors in Domestic Animals. 3 edn., California, University of California Press, 1990: 518550.
  • 35
    Strieter RM, Polverini PJ, Arenberg DA and Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock 1995; 4: 155160.
  • 36
    Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. Journal of Experimental Medicine 1995; 182: 155162.
  • 37
    Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539545.
  • 38
    Osborne J, Moore PS and Chang Y. KSHVencoded viral IL-6 activates multiple human IL-6 signalling pathways. Human Immunology 1999; 60: 921927.
  • 39
    Bommert K, Bargou RC and Stuhmer T. Signalling and survival pathways in multiple myeloma. European Journal of Cancer 2006; 42: 15741580.
  • 40
    Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2003; 103: 32163221.
  • 41
    Berger FG. The interleukin-6 gene a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Research and Treatment 2004; 88: 281285.
  • 42
    Trikha M, Corringham R, Klein B and Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer a review of the rationale and clinical evidence. Clinical Cancer Research 2003; 9: 46534665.
  • 43
    Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y and Fisher PB. Interleukin-10 and related cytokines and receptors. Annual Review of Immunology 2004; 22: 929979.
  • 44
    Schottelius AJ, Mayo MW, Sartor RB and Baldwin AS Jr. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. Journal of Biological Chemistry 1999; 274: 3186831874.
  • 45
    Hoentjen F, Sartor RB, Ozaki M and Jobin C. STAT3 regulates NF-kB recruitment to the IL-12p40 promoter in dendritic cells. Blood 2005; 105: 689696.
  • 46
    Moore KW, de Waal Malefyt R, Coffman RL and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annual Review Immunology 2001; 19: 683765.
  • 47
    Kundu N and Fulton AM. Interleukin-10 inhibits tumor metastasis, down-regulates MHC class I, and enhances NK lysis. Cellular Immunology 1997; 180: 5561.
  • 48
    Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Current Opinion in Immunology 2005; 17: 180186.
  • 49
    Huang S, Ullrich SE and Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. Journal of Interferon and Cytokine Research 1999; 19: 697703.
  • 50
    Sredni B, Weil M, Khomenok G, et al. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Research 2004; 64: 18431852.
  • 51
    Lech-Maranda E, Bienvenu J, Michallet AS, et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. European Cytokine Network 2006; 17: 6066.
  • 52
    Czarneski J, Lin YC, Chong S, et al. Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia 2004; 18: 597606.
  • 53
    García-Hernández ML, Hernández-Pando R, Gariglio P and Berumen J. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 2002; 105: 231243.
  • 54
    Mocellin S, Marincola FM and Young HA. Interleukin-10 and the immune response against cancer a counterpoint. Journal of Leukocyte Biology 2005; 78: 10431051.